Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RR001 + Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma
NCT06861452Phase 2Recruiting
- Sponsor
- EIR Biotherapies
- Start
- Jun 2025
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Bone Marrow HSCs, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of RR001 in pancreatic adenocarcinoma (PDAC), sponsored by EIR Biotherapies. Started Jun 2025; status: recruiting.
02
Drugs
RR001
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06861452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861452.